Personalis outlines 170% clinical test volume growth target for 2026 as reimbursement and MRD strategy accelerate
Source: SeekingAlpha
2026-02-26 23:38:19 ET
More on Personalis
- Personalis, Inc. (PSNL) Q4 2025 Earnings Call Transcript
- Personalis rises on Medicare coverage for NeXT Personal cancer test
- Personalis expects FY 2025 revenue between $69M and $70M
- Seeking Alpha’s Quant Rating on Personalis
- Historical earnings data for Personalis
Read the full article on Seeking Alpha
For further details see:
Personalis outlines 170% clinical test volume growth target for 2026 as reimbursement and MRD strategy accelerate
Personalis Inc.
NASDAQ: PSNL
PSNL Trading
-2.77% G/L:
$7.71 Last:
587,454 Volume:
$7.65 Open:
PSNL Latest News
March 01, 2026 11:23:49 pm
Lightspeed Makes a Big Bet on Self-Driving Trucks, Loading Up on 7 Million Shares of Kodiak AI (KDK)
February 26, 2026 04:01:00 pm
Personalis Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights
PSNL Stock Data
$769,933,697
50,352,065
0.12%
38
N/A
Medical Diagnostics & Screening
Healthcare
US
Fremont
